TBio-4101
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TBio-4101, covering 2026-04-01 to 2026-04-02. Get the full timeline:
Most recent: Clinical Trial Update: Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma [Phase 1]